CIPROFLOXACIN HYDROCHLORIDE

Post-LOE

ciprofloxacin otic solution, 0.2%

Alembic

ANDAOTICSOLUTION/DROPS

Approved

Nov 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CIPROFLOXACIN HYDROCHLORIDE (ciprofloxacin otic solution, 0.2%) by Alembic is cytochrome p450 1a2 inhibitors [moa]. Approved for acute otitis externa due to susceptible isolates of pseudomonas aeruginosa, staphylococcus aureus. First approved in 2024.

Drug data last refreshed 13h ago

Mechanism of Action

Cytochrome P450 1A2 Inhibitors

Pharmacologic Class:

Fluoroquinolone Antibacterial

Indications (2)

acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa Staphylococcus aureus

Worked on CIPROFLOXACIN HYDROCHLORIDE at Alembic? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.